Preliminary clinical study of weekly recombinant human endostatin as a hypoxic tumour cell radiosensitiser combined with radiotherapy in the treatment of NSCLC

• Published in: Clinical & translational oncology 2012-06, Vol.14 (6), p.465-470
• Main Authors: Jiang, Xiao-Dong, Qiao, Yun, Dai, Peng, Wu, Jin, Song, Da-An, Li, Shi-Qiu, Fan, Yue-Wei
• Format: Article
• Language: English
• Subjects: Aged; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - radiotherapy; Cell Hypoxia; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Endostatins - administration & dosage; Endostatins - therapeutic use; Female; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Lung Neoplasms - radiotherapy; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Radiation-Sensitizing Agents - administration & dosage; Radiation-Sensitizing Agents - therapeutic use; Radiotherapy, Intensity-Modulated; Recombinant Proteins - administration & dosage; Recombinant Proteins - therapeutic use
• ISSN: 1699-048X; 1699-3055
• DOI: 10.1007/s12094-012-0825-z

Objective To investigate the clinical effects and adverse effects of weekly recombinant human endostatin (RHES) as a hypoxic tumour cell radiosensitiser combined with radiotherapy in the treatment of non-small-cell lung cancer (NSCLC). Methods Fifty hypoxia-positive cases of pathology-diagnosed NSCLC (stage I–III) were randomly divided into a RHES+radiotherapy group (25 cases) and a radiotherapy alone group (25 cases). Intensity-modulated radiotherapy (IMRT) with a total dose of 60 Gy/30F/6W was adopted in the two groups. Target area included primary foci and metastatic lymph nodes. In the RHES+radiotherapy group, RHES (15 mg/day) was intravenously given during the first week. The therapeutic effects and adverse reactions were evaluated after treatment. Results In the RHES+radiotherapy and radiotherapy alone groups, the total effective rates (CR+PR) were 80% and 44% (χ 2 =6.87, p =0.009), respectively. The one-year and two-year local control rates were (78.9±8.4)% and (68.1±7.8)% ( p =0.027), and (63.6±7.2)% and (43.4±5.7)% ( p =0.022), respectively. The median progression-free survival was (21.1±0.97) and (16.5±0.95) months, respectively. The one-year and two-year overall survival rates were (83.3±7.2)% and (76.6±9.3)% ( p =0.247), and (46.3±2.4)% and (37.6±9.1)% ( p =0.218), respectively. Conclusion RHES combined with radiotherapy within the first week has better short-term therapeutic effects and local control rate, and no severe adverse reactions in treatment of NSCLC. However, it failed to significantly improve the one-year and two-year overall survival rates.